Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Modulators of nucleoside metabolism in the therapy of brain diseases.

Boison D.

Curr Top Med Chem. 2011;11(8):1068-86. Review.

2.

Adenosine and related drugs in brain diseases: present and future in clinical trials.

Lopes LV, Sebastião AM, Ribeiro JA.

Curr Top Med Chem. 2011;11(8):1087-101. Review.

PMID:
21401493
3.

Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain.

Ferré S, Diamond I, Goldberg SR, Yao L, Hourani SM, Huang ZL, Urade Y, Kitchen I.

Prog Neurobiol. 2007 Dec;83(5):332-47. Epub 2007 May 1. Review.

4.

The role of adenosine in the regulation of sleep.

Huang ZL, Urade Y, Hayaishi O.

Curr Top Med Chem. 2011;11(8):1047-57. Review.

PMID:
21401496
5.

Role of the purinergic signaling in epilepsy.

Cieślak M, Wojtczak A, Komoszyński M.

Pharmacol Rep. 2017 Feb;69(1):130-138. doi: 10.1016/j.pharep.2016.09.018. Epub 2016 Sep 22. Review.

PMID:
27915186
6.
7.

Adenosine as a modulator of brain activity.

Boison D.

Drug News Perspect. 2007 Dec;20(10):607-11. doi: 10.1358/dnp.2007.20.10.1181353. Review.

PMID:
18301794
8.

Exploring the Role of N6-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice ∇.

Petrelli R, Scortichini M, Kachler S, Boccella S, Cerchia C, Torquati I, Del Bello F, Salvemini D, Novellino E, Luongo L, Maione S, Jacobson KA, Lavecchia A, Klotz KN, Cappellacci L.

J Med Chem. 2017 May 25;60(10):4327-4341. doi: 10.1021/acs.jmedchem.7b00291. Epub 2017 May 5.

PMID:
28447789
9.

Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors.

McGaraughty S, Cowart M, Jarvis MF, Berman RF.

Curr Top Med Chem. 2005;5(1):43-58. Review.

PMID:
15638777
10.

Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.

Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonça A.

Prog Neurobiol. 2007 Dec;83(5):310-31. Epub 2007 Sep 29. Review.

PMID:
18023959
11.

Modulation of adenosinergic system and its application for the treatment of epilepsy.

Świąder MJ, Kotowski J, Łuszczki JJ.

Pharmacol Rep. 2014 Jun;66(3):335-42. doi: 10.1016/j.pharep.2013.10.005. Epub 2014 Apr 13. Review.

PMID:
24905507
12.

Involvement of CD73, equilibrative nucleoside transporters and inosine in rhythm and conduction disturbances mediated by adenosine A1 and A2A receptors in the developing heart.

Robin E, Sabourin J, Marcillac F, Raddatz E.

J Mol Cell Cardiol. 2013 Oct;63:14-25. doi: 10.1016/j.yjmcc.2013.06.008. Epub 2013 Jul 6.

PMID:
23837961
13.

Area, age and gender dependence of the nucleoside system in the brain: a review of current literature.

Kovács Z, Juhász G, Palkovits M, Dobolyi A, Kékesi KA.

Curr Top Med Chem. 2011;11(8):1012-33. Review.

PMID:
21401498
14.

Adenosinergic signaling in epilepsy.

Boison D.

Neuropharmacology. 2016 May;104:131-9. doi: 10.1016/j.neuropharm.2015.08.046. Epub 2015 Sep 1. Review.

15.

Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.

Abbracchio MP, Cattabeni F.

Ann N Y Acad Sci. 1999;890:79-92.

PMID:
10668415
16.
17.

Adenosine A2A receptors and neuroprotection.

Ongini E, Adami M, Ferri C, Bertorelli R.

Ann N Y Acad Sci. 1997 Oct 15;825:30-48. Review.

PMID:
9369973
18.

Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.

He W, Mazumder A, Wilder T, Cronstein BN.

FASEB J. 2013 Sep;27(9):3446-54. doi: 10.1096/fj.13-231233. Epub 2013 May 16.

19.

Dual blockade of the A1 and A2A adenosine receptor prevents amyloid beta toxicity in neuroblastoma cells exposed to aluminum chloride.

Giunta S, Andriolo V, Castorina A.

Int J Biochem Cell Biol. 2014 Sep;54:122-36. doi: 10.1016/j.biocel.2014.07.009. Epub 2014 Jul 21.

PMID:
25058312
20.

Adenosine A1 and A2A receptors are not upstream of caffeine's dopamine D2 receptor-dependent aversive effects and dopamine-independent rewarding effects.

Sturgess JE, Ting-A-Kee RA, Podbielski D, Sellings LH, Chen JF, van der Kooy D.

Eur J Neurosci. 2010 Jul;32(1):143-54. doi: 10.1111/j.1460-9568.2010.07247.x. Epub 2010 Jun 22.

Supplemental Content

Support Center